Clinical Validation of a Urinary Exosome Gene Signature in Men Presenting for Suspicion of Prostate Cancer

NCT02702856 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2016-03-09

No results posted yet for this study

Summary

Validate a non-DRE exosome gene expression test, with an NPV \>/= 90% certainty, will exclude the presence of high gleason grade/ score (\>/=7) prostate cancer in a prostate needle biopsy.

Conditions

Interventions

OTHER

ExoIntelliScore Prostate

Sponsors & Collaborators

  • Exosome Diagnostics, Inc.

    lead INDUSTRY

Principal Investigators

  • Roger Tun · Exosome Diagnostics, Inc.

Eligibility

Min Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2015-04-30
Completion
2015-06-30

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02702856 on ClinicalTrials.gov